Camelot Portfolios LLC purchased a new position in shares of Quest Diagnostics Inc (NYSE:DGX) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,210 shares of the medical research company’s stock, valued at approximately $237,000.

Several other hedge funds have also bought and sold shares of DGX. Pearl River Capital LLC purchased a new position in shares of Quest Diagnostics during the second quarter worth approximately $28,000. Wealthcare Advisory Partners LLC purchased a new position in shares of Quest Diagnostics during the second quarter worth approximately $29,000. Berman Capital Advisors LLC raised its stake in shares of Quest Diagnostics by 47.7% during the second quarter. Berman Capital Advisors LLC now owns 319 shares of the medical research company’s stock worth $32,000 after acquiring an additional 103 shares in the last quarter. NuWave Investment Management LLC raised its stake in shares of Quest Diagnostics by 108.4% during the third quarter. NuWave Investment Management LLC now owns 346 shares of the medical research company’s stock worth $36,000 after acquiring an additional 180 shares in the last quarter. Finally, CWM LLC raised its stake in shares of Quest Diagnostics by 61.1% during the second quarter. CWM LLC now owns 464 shares of the medical research company’s stock worth $47,000 after acquiring an additional 176 shares in the last quarter. 89.76% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts have commented on DGX shares. Goldman Sachs Group downgraded shares of Quest Diagnostics from a “neutral” rating to a “sell” rating and decreased their price target for the stock from $90.00 to $85.00 in a research note on Monday, July 15th. Morgan Stanley lifted their price target on shares of Quest Diagnostics from $111.00 to $121.00 and gave the stock an “overweight” rating in a research note on Friday, August 23rd. Canaccord Genuity lifted their price target on shares of Quest Diagnostics from $108.00 to $112.00 and gave the stock a “buy” rating in a research note on Wednesday, July 24th. Credit Suisse Group lifted their price target on shares of Quest Diagnostics from $99.00 to $105.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Quest Diagnostics from $100.00 to $111.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $105.06.

In other news, CAO Michael J. Deppe sold 5,000 shares of the business’s stock in a transaction on Tuesday, September 17th. The shares were sold at an average price of $106.00, for a total transaction of $530,000.00. Following the sale, the chief accounting officer now owns 28,671 shares in the company, valued at approximately $3,039,126. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 1.86% of the company’s stock.

Shares of DGX stock traded up $0.73 during mid-day trading on Wednesday, reaching $105.54. 3,424 shares of the company’s stock traded hands, compared to its average volume of 774,834. Quest Diagnostics Inc has a 12 month low of $78.95 and a 12 month high of $107.97. The company has a market cap of $13.94 billion, a P/E ratio of 16.69, a P/E/G ratio of 2.16 and a beta of 0.87. The company has a quick ratio of 0.77, a current ratio of 0.82 and a debt-to-equity ratio of 0.58. The company’s 50-day moving average price is $104.35 and its 200-day moving average price is $99.52.

Quest Diagnostics (NYSE:DGX) last announced its earnings results on Tuesday, July 23rd. The medical research company reported $1.73 EPS for the quarter, beating the Zacks’ consensus estimate of $1.69 by $0.04. Quest Diagnostics had a net margin of 9.64% and a return on equity of 15.05%. The firm had revenue of $1.95 billion for the quarter, compared to analysts’ expectations of $1.94 billion. During the same quarter in the previous year, the business posted $1.75 EPS. The company’s quarterly revenue was up 1.8% on a year-over-year basis. Equities analysts predict that Quest Diagnostics Inc will post 6.5 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, October 21st. Stockholders of record on Friday, October 4th will be issued a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.01%. The ex-dividend date is Thursday, October 3rd. Quest Diagnostics’s dividend payout ratio (DPR) is presently 33.60%.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Read More: Are all No-Load Funds Equal?

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Inc (NYSE:DGX).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.